Varenicline
- Generic Name
- Varenicline
- Brand Names
- Champix, Chantix, Tyrvaya
- Drug Type
- Small Molecule
- Chemical Formula
- C13H13N3
- CAS Number
- 249296-44-4
- Unique Ingredient Identifier
- W6HS99O8ZO
- Background
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A...
- Indication
For use as an aid in smoking cessation.
Varenicline as a nasal spray is indicated for the symptomatic treatment of dry eye disease.
- Associated Conditions
- Dry Eye Syndrome (DES)
- Associated Therapies
- Smoking, Cessation
A 6-Week Multicenter Trial Of Varenicline Tartrate For Cognitive Impairment In Subjects With Schizophrenia
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2009-02-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00743847
Varenicline-Methamphetamine Interaction Study (2008)
- Conditions
- Interventions
- First Posted Date
- 2008-08-13
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- Baylor College of Medicine
- Registration Number
- NCT00733967
Effects of Varenicline on Cigarette Self Administration
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00731055
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2024-02-08
- Target Recruit Count
- 10
- Registration Number
- NCT00727103
- Locations
- 🇺🇸
SUNY Upstate Medical University, Syracuse, New York, United States
Human Laboratory Study Of Varenicline in Smokers
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2017-12-27
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00709696
- Locations
- 🇺🇸
Tobacco Use Research Center, Minneapolis, Minnesota, United States
Varenicline (Chantix™) for the Treatment of Alcohol Dependence
- First Posted Date
- 2008-06-26
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 40
- Registration Number
- NCT00705523
- Locations
- 🇺🇸
University of Pennsylvania Treatment Research Center, Philadelphia, Pennsylvania, United States
Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- University of British Columbia
- Registration Number
- NCT00702793
Varenicline to Reduce Alcohol Consumption in Heavy Drinkers
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Vijay Ramchandani, Ph.D.
- Target Recruit Count
- 50
- Registration Number
- NCT00695500
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2009-06-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT00694044
- Locations
- 🇺🇸
Pfizer Investigational Site, Orlando, Florida, United States
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
- First Posted Date
- 2008-06-05
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 659
- Registration Number
- NCT00691483
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.